Table of Contents Purpose of This PDQ Summary General Information Cellular Classification Stage Information Stage I Merkel Cell Carcinoma
Stage II Merkel Cell Carcinoma Stage III Merkel Cell Carcinoma Recurrent Merkel Cell Carcinoma Get More Information From NCI Changes to This Summary (12/13/2007) More Information
Purpose of This PDQ Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of Merkel cell carcinoma. This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board 1.
Information about the following is included in this summary:
- Epidemiology and clinical presentation.
- Cellular classification.
- Staging.
- Treatment options by cancer stage.
This summary is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Some of the reference citations in the summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a formal evidence ranking system 2 in developing its level-of-evidence designations. Based on the strength of the available evidence, treatment options are described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for reimbursement determinations.
This summary is available in a patient version 3, written in less technical language, and in Spanish 4. General Information
Merkel cell carcinoma (MCC), or neuroendocrine carcinoma of the skin, is an
uncommon and often aggressive malignancy that has a poor prognosis. More than 400 new cases of MCC occur in the United States each year, and the mortality rate is approximately 25%.[1] MCC is predominantly a tumor of the
elderly, and most reported cases have occurred in white subjects.[2-6] It
occurs most frequently in the head and neck region and the extremities and
has a predilection for the periocular region.[2,3,5,6] People treated with methoxsalen and ultraviolet A for psoriasis and people who are immunocompromised have an increased incidence of developing MCC.[7]
The Merkel
cell is located in or near the basal layer of the epidermis and is closely
associated with terminal axons.[2,3,8] While MCC may be
difficult to diagnose, it usually presents as a painless, indurated, solitary
dermal nodule with a slightly erythematous to deeply violaceous color. MCC
frequently involves regional lymph nodes (10%–45% at initial
presentation),[2-5,9] and between 50% and 75% of patients will develop
regional lymph node metastases at some time during the course of their
disease.[2-4] Distant metastases eventually occur in as many as 50% of
patients, with lymph nodes, the liver, bone, brain, lung, and skin the most
common sites of distant involvement.[2,3,5,6,10] MCC may progress rapidly and similarly to aggressive melanoma. After primary tumor excision, local recurrence develops in 25% to 44% of patients; this has been attributed to inadequate surgical margins.[2,4,5]
References
-
Nghiem P, McKee PH, Haynes HA: Merkel cell (cutaneous neuroendocrine) carcinoma. In: Sober AJ, Haluska FG, eds.: Skin Cancer. Hamilton, Ontario: BC Decker Inc., 2001., pp 127-141.
-
Haag ML, Glass LF, Fenske NA: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21 (8): 669-83, 1995.
[PUBMED Abstract]
-
Ratner D, Nelson BR, Brown MD, et al.: Merkel cell carcinoma. J Am Acad Dermatol 29 (2 Pt 1): 143-56, 1993.
[PUBMED Abstract]
-
Yiengpruksawan A, Coit DG, Thaler HT, et al.: Merkel cell carcinoma. Prognosis and management. Arch Surg 126 (12): 1514-9, 1991.
[PUBMED Abstract]
-
Goepfert H, Remmler D, Silva E, et al.: Merkel cell carcinoma (endocrine carcinoma of the skin) of the head and neck. Arch Otolaryngol 110 (11): 707-12, 1984.
[PUBMED Abstract]
-
Gollard R, Weber R, Kosty MP, et al.: Merkel cell carcinoma: review of 22 cases with surgical, pathologic, and therapeutic considerations. Cancer 88 (8): 1842-51, 2000.
[PUBMED Abstract]
-
Lunder EJ, Stern RS: Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet A radiation. N Engl J Med 339 (17): 1247-8, 1998.
[PUBMED Abstract]
-
Gould VE, Moll R, Moll I, et al.: Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab Invest 52 (4): 334-53, 1985.
[PUBMED Abstract]
-
Tai PT, Yu E, Winquist E, et al.: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18 (12): 2493-9, 2000.
[PUBMED Abstract]
-
Marks ME, Kim RY, Salter MM: Radiotherapy as an adjunct in the management of Merkel cell carcinoma. Cancer 65 (1): 60-4, 1990.
[PUBMED Abstract]
Cellular Classification
Merkel cell carcinoma (MCC) is usually found within the dermis but may extend into the subcutaneous
tissue. The combination of vesicular nuclei with small nucleoli, abundant
mitoses, and apoptosis is characteristic of this tumor when
evaluated within the context of certain architectural features.
Histologically, MCC has been classified into three distinct subtypes:[1-3]
Trabecular
- Cells are arranged in distinctly organoid clusters and
trabeculae with occasional ribbons.
- Individual cells are round to
polygonal in shape and are compactly arranged.
- Cell
cytoplasm is comparatively abundant and often well defined.
- Mitoses
are few to moderate in number.
- The tumor is usually found
adjacent to adnexal structures, particularly hair follicles.
- Trabecular is the
least frequent histologic pattern identified.
Intermediate
- The tumor exhibits a solid and diffuse growth pattern.
- Cells are
less compactly arranged, and the cytoplasm is less abundant than in the
trabecular type.
- Mitoses and focal areas of necrosis are frequently seen.
- Intermediate tumors arise adjacent to adnexa but may also invade the epidermis.
- Intermediate tumors may behave in a clinically more aggressive manner than trabecular tumors.
- Intermediate is the most frequent histologic subtype identified.
Small cell
- The tumor closely mimics small cell tumors of other sites.
- The
tumors arise in the dermis and appear as solid sheets and clusters of
cells.
- Areas of necrosis and crushing artifact are frequently seen.
- The
clinical behavior of small cell tumors appears to be as aggressive as that of
intermediate tumors.
References
-
Haag ML, Glass LF, Fenske NA: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21 (8): 669-83, 1995.
[PUBMED Abstract]
-
Ratner D, Nelson BR, Brown MD, et al.: Merkel cell carcinoma. J Am Acad Dermatol 29 (2 Pt 1): 143-56, 1993.
[PUBMED Abstract]
-
Gould VE, Moll R, Moll I, et al.: Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms. Lab Invest 52 (4): 334-53, 1985.
[PUBMED Abstract]
Stage Information
No widely accepted or standardized staging classification based upon
prognosis is available. A commonly used staging system is based upon clinical presentation:[1]
- Stage IA: Primary tumor smaller than 2 cm with no evidence of spread to lymph nodes or distant
sites.
- Stage IB: Primary tumor 2 cm or larger with no evidence of spread to lymph nodes or distant sites.
- Stage II: Regional node involvement but no evidence of distant metastases.
- Stage III: Presence of systemic metastases beyond the regional lymph nodes.
References
-
Aasi SZ, Leffell DJ: Cancer of the skin. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2005, pp 1717-44.
Stage I Merkel Cell Carcinoma
Note: Some citations in the text of this section are followed by a level of
evidence. The PDQ editorial boards use a formal ranking system to help the
reader judge the strength of evidence linked to the reported results of a
therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence 2 for more
information.)
Wide local excision has been recommended whenever possible for patients with stage I Merkel cell carcinoma (MCC).[1-3][Level of evidence: 3iiiDiii] Frozen section control has also been recommended, especially
when the tumor is in an anatomical site that is not amenable to wide margins.
Some authors have advocated the use of Mohs micrographic surgery as a
tissue-sparing technique. The reported relapse rate is similar to or better than that of wide excision, but comparatively few cases have been treated in this
manner and definitive clinical studies have yet to be conducted.[2,4,5]
The role of elective lymph node dissection (ELND) in the absence
of clinically positive nodes is unclear. ELND has been recommended for
larger tumors, tumors with more than 10 mitoses per high-power field,
lymphatic or vascular invasion, and the small-cell histologic subtypes.[1-3]
Sentinel lymph node (SLN) biopsy has been suggested as an alternative to complete ELND for the proper staging of MCC. SLN biopsy has lower morbidity than complete nodal dissection. Furthermore, for MCC sites with indeterminate lymphatic drainage, such as those on the back, SLN biopsy techniques can be used to identify the pertinent lymph node bed(s). Several reports have found the use of SLN biopsy techniques in patients with MCC to be reliable and reproducible.[6-9] A meta-analysis found that SLN positivity is strongly predictive of a high short-term risk of recurrence and that subsequent therapeutic lymph node dissection was effective in preventing short-term regional nodal recurrence.[10]
Because of the aggressive nature of MCC and the high incidence of locoregional recurrence after surgery alone, many authors advocate adjuvant radiation therapy to the primary site and to the regional lymph node basin.[1,2,4,11] Convincing data from prospective trials are not available; based on retrospective reviews, however, radiation therapy has been used in patients with larger tumors, tumors with lymphatic invasion, tumors approaching the surgical margins of resection, and locally unresectable tumors. Improved locoregional control has been achieved with resection followed by radiation therapy as compared to surgery alone in some retrospective nonrandomized reports.[12] Studies suggest that the appropriate total dose is about 50 Gy to the surgical bed and the draining regional lymphatics, delivered in 2 Gy fractions.[1,2,11-13] For patients with unresected tumors or tumors with microscopic evidence of spread beyond resected margins, higher doses of 56 Gy to 65 Gy have been recommended.[1][Level of evidence: 3iiiDiii]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage I neuroendocrine carcinoma of the skin 5. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site 6.
References
-
Haag ML, Glass LF, Fenske NA: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21 (8): 669-83, 1995.
[PUBMED Abstract]
-
Ratner D, Nelson BR, Brown MD, et al.: Merkel cell carcinoma. J Am Acad Dermatol 29 (2 Pt 1): 143-56, 1993.
[PUBMED Abstract]
-
Yiengpruksawan A, Coit DG, Thaler HT, et al.: Merkel cell carcinoma. Prognosis and management. Arch Surg 126 (12): 1514-9, 1991.
[PUBMED Abstract]
-
Goepfert H, Remmler D, Silva E, et al.: Merkel cell carcinoma (endocrine carcinoma of the skin) of the head and neck. Arch Otolaryngol 110 (11): 707-12, 1984.
[PUBMED Abstract]
-
Nghiem P, McKee PH, Haynes HA: Merkel cell (cutaneous neuroendocrine) carcinoma. In: Sober AJ, Haluska FG, eds.: Skin Cancer. Hamilton, Ontario: BC Decker Inc., 2001., pp 127-141.
-
Messina JL, Reintgen DS, Cruse CW, et al.: Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol 4 (5): 389-95, 1997 Jul-Aug.
[PUBMED Abstract]
-
Hill AD, Brady MS, Coit DG: Intraoperative lymphatic mapping and sentinel lymph node biopsy for Merkel cell carcinoma. Br J Surg 86 (4): 518-21, 1999.
[PUBMED Abstract]
-
Wasserberg N, Schachter J, Fenig E, et al.: Applicability of the sentinel node technique to Merkel cell carcinoma. Dermatol Surg 26 (2): 138-41, 2000.
[PUBMED Abstract]
-
Rodrigues LK, Leong SP, Kashani-Sabet M, et al.: Early experience with sentinel lymph node mapping for Merkel cell carcinoma. J Am Acad Dermatol 45 (2): 303-8, 2001.
[PUBMED Abstract]
-
Mehrany K, Otley CC, Weenig RH, et al.: A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. Dermatol Surg 28 (2): 113-7; discussion 117, 2002.
[PUBMED Abstract]
-
Gollard R, Weber R, Kosty MP, et al.: Merkel cell carcinoma: review of 22 cases with surgical, pathologic, and therapeutic considerations. Cancer 88 (8): 1842-51, 2000.
[PUBMED Abstract]
-
Goessling W, McKee PH, Mayer RJ: Merkel cell carcinoma. J Clin Oncol 20 (2): 588-98, 2002.
[PUBMED Abstract]
-
Marks ME, Kim RY, Salter MM: Radiotherapy as an adjunct in the management of Merkel cell carcinoma. Cancer 65 (1): 60-4, 1990.
[PUBMED Abstract]
Stage II Merkel Cell Carcinoma
Note: Some citations in the text of this section are followed by a level of
evidence. The PDQ editorial boards use a formal ranking system to help the
reader judge the strength of evidence linked to the reported results of a
therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence 2 for more
information.)
Wide local excision of the primary tumor, whenever possible, and regional lymph
node dissection have been recommended for patients with stage II Merkel cell carcinoma (MCC).[1,2][Level of evidence: 3iiiDiii] Because of the aggressive nature of MCC and the high incidence of locoregional recurrence after surgery alone, many authors advocate adjuvant radiation therapy to the primary site and to the regional lymph node basin.[1-4] Convincing data from prospective trials are not available; based on retrospective reviews, however, radiation therapy has been used in patients with larger tumors, tumors with lymphatic invasion, tumors approaching the surgical margins of resection, and locally unresectable tumors. Improved locoregional control has been achieved with resection followed by radiation therapy as compared with surgery alone in some retrospective nonrandomized reports.[5] Studies suggest that the appropriate total dose is about 50 Gy to the surgical bed and the draining regional lymphatics, delivered in 2 Gy fractions.[1,2,4-6] For patients with unresected tumors or tumors with microscopic evidence of spread beyond resected margins, higher doses of 56 Gy to 65 Gy have been recommended.[1][Level of evidence: 3iiiDiii]
The
role of adjuvant chemotherapy remains unproven but is advocated by some
authors.[1,6,7] Studies have shown response rates in the range of 60% in the setting of locally advanced or metastatic disease using chemotherapy regimens similar to those used for patients with small cell lung cancer.[5] (See the PDQ summary
on Small Cell Lung Cancer Treatment 7 for chemotherapeutic options.) The benefit of chemotherapy as adjuvant therapy is yet to be determined.
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage II neuroendocrine carcinoma of the skin 8. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site 6.
References
-
Haag ML, Glass LF, Fenske NA: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21 (8): 669-83, 1995.
[PUBMED Abstract]
-
Yiengpruksawan A, Coit DG, Thaler HT, et al.: Merkel cell carcinoma. Prognosis and management. Arch Surg 126 (12): 1514-9, 1991.
[PUBMED Abstract]
-
Goepfert H, Remmler D, Silva E, et al.: Merkel cell carcinoma (endocrine carcinoma of the skin) of the head and neck. Arch Otolaryngol 110 (11): 707-12, 1984.
[PUBMED Abstract]
-
Marks ME, Kim RY, Salter MM: Radiotherapy as an adjunct in the management of Merkel cell carcinoma. Cancer 65 (1): 60-4, 1990.
[PUBMED Abstract]
-
Goessling W, McKee PH, Mayer RJ: Merkel cell carcinoma. J Clin Oncol 20 (2): 588-98, 2002.
[PUBMED Abstract]
-
Tai PT, Yu E, Winquist E, et al.: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18 (12): 2493-9, 2000.
[PUBMED Abstract]
-
Feun LG, Savaraj N, Legha SS, et al.: Chemotherapy for metastatic Merkel cell carcinoma. Review of the M.D. Anderson Hospital's experience. Cancer 62 (4): 683-5, 1988.
[PUBMED Abstract]
Stage III Merkel Cell Carcinoma
Note: Some citations in the text of this section are followed by a level of
evidence. The PDQ editorial boards use a formal ranking system to help the
reader judge the strength of evidence linked to the reported results of a
therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence 2 for more
information.)
Chemotherapy is the treatment most often used for patients with stage III
Merkel cell carcinoma (MCC).[1-5][Level of evidence: 3iiiDiv] Because of
morphologic and immunohistochemical similarities, the regimens employed are
similar to those used for patients with small cell lung cancer. (See the PDQ summary
on Small Cell Lung Cancer Treatment 7 for chemotherapeutic options.) Cyclophosphamide, doxorubicin, and vincristine and etoposide plus cisplatin are the most commonly used regimens. MCC often
responds to chemotherapy initially, but the response is usually short-lived and
the impact of chemotherapy on survival is uncertain.[1-5]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with stage III neuroendocrine carcinoma of the skin 9. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site 6.
References
-
Haag ML, Glass LF, Fenske NA: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21 (8): 669-83, 1995.
[PUBMED Abstract]
-
Ratner D, Nelson BR, Brown MD, et al.: Merkel cell carcinoma. J Am Acad Dermatol 29 (2 Pt 1): 143-56, 1993.
[PUBMED Abstract]
-
Tai PT, Yu E, Winquist E, et al.: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18 (12): 2493-9, 2000.
[PUBMED Abstract]
-
Feun LG, Savaraj N, Legha SS, et al.: Chemotherapy for metastatic Merkel cell carcinoma. Review of the M.D. Anderson Hospital's experience. Cancer 62 (4): 683-5, 1988.
[PUBMED Abstract]
-
Voog E, Biron P, Martin JP, et al.: Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85 (12): 2589-95, 1999.
[PUBMED Abstract]
Recurrent Merkel Cell Carcinoma
Treatment options for patients with local recurrence include regional lymph node dissection and adjuvant
radiation therapy if the regional draining nodes have not
been previously treated.[1,2] An alternative approach for patients who have not had a complete regional lymph node dissection would be a sentinel lymph node biopsy and complete nodal dissection if positive nodes are identified.[3]
When possible, adjuvant radiation therapy of the site of recurrence as well as of the regional lymph node beds is recommended after surgery.[4,5] Chemotherapy may be an option for patients with
unresectable recurrent tumors or for patients who have received their maximum
tolerated radiation dose.[1]
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent neuroendocrine carcinoma of the skin 10. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site 6.
References
-
Haag ML, Glass LF, Fenske NA: Merkel cell carcinoma. Diagnosis and treatment. Dermatol Surg 21 (8): 669-83, 1995.
[PUBMED Abstract]
-
Ratner D, Nelson BR, Brown MD, et al.: Merkel cell carcinoma. J Am Acad Dermatol 29 (2 Pt 1): 143-56, 1993.
[PUBMED Abstract]
-
Allen PJ, Zhang ZF, Coit DG: Surgical management of Merkel cell carcinoma. Ann Surg 229 (1): 97-105, 1999.
[PUBMED Abstract]
-
Nghiem P, McKee PH, Haynes HA: Merkel cell (cutaneous neuroendocrine) carcinoma. In: Sober AJ, Haluska FG, eds.: Skin Cancer. Hamilton, Ontario: BC Decker Inc., 2001., pp 127-141.
-
Herbst A, Haynes HA, Nghiem P: The standard of care for Merkel cell carcinoma should include adjuvant radiation and lymph node surgery. J Am Acad Dermatol 46 (4): 640-2, 2002.
[PUBMED Abstract]
Get More Information From NCI
Call 1-800-4-CANCER
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 9:00 a.m. to 4:30 p.m. Deaf and hard-of-hearing callers with TTY equipment may call 1-800-332-8615. The call is free and a trained Cancer Information Specialist is available to answer your questions.
Chat online
The NCI's LiveHelp® 11 online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 9:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
- NCI Public Inquiries Office
- Suite 3036A
- 6116 Executive Boulevard, MSC8322
- Bethesda, MD 20892-8322
Search the NCI Web site
The NCI Web site 12 provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use our “Best Bets” search box in the upper right hand corner of each Web page. The results that are most closely related to your search term will be listed as Best Bets at the top of the list of search results.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
Find Publications
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator 13. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237), TTY at 1-800-332-8615. Changes to This Summary (12/13/2007)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Purpose of This PDQ Summary 14 as a new section. More Information
About PDQ
Additional PDQ Summaries
Important:
This information is intended mainly for use by doctors and other health care professionals. If you have questions about this topic, you can ask your doctor, or call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). |